Advertisement

Antirheumatika und Antiphlogistika

  • Gerhard Schmidt

Zusammenfassung

In der Therapie rheumatischer Erkrankungen einschließlich degenerativer Veränderungen werden vorzugsweise nichtsteroidale Antiphlogistika eingesetzt. Mit ihnen gelingt es, den entzündlichen Prozeß zurückzudrängen, die Beweglichkeit zu verbessern und den entzündlichen Schmerz zu vermindern. Für Glucocorticoide (vgl. ) sind in der Therapie der rheumatoiden Arthritis in den letzten Jahren die Indikationen für eine niedrig dosierte Therapie ausgeweitet worden. Die remissionsinduzierenden antirheumatischen Arzneimittel (langfristig wirkende Antirheumatika, auch als „Basisthera-peutika“ bezeichnet) haben wegen ihrer seltenen Indikation mengenmäßig nur einen geringen Anteil an den Verordnungen der Antirheumatika und Antiphlogistika. Eine kritische Beachtung verdienen die hierzulande besonders viel verwendeten Externa (Rheumasalben und Einreibungen), für die allerdings die abgerechneten Verordnungen 1999 gegenüber dem Vorjahr weiter zurückgegangen sind (Abbildung 16.1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneimittelkommission der deutschen Ärzteschaft (1997): Empfehlungen zur Therapie von degenerativen Gelenkerkrankungen. Arzneiverordnung in der Praxis. Sonderheft 5, 8.Google Scholar
  2. Bauer H.W., Klasser M., von Hanstein K.L., Rolinger H., Schladitz G. et al. (1999): Oxaceprol is as effective as diclofenac in the therapy of osteoarthritis of the knee and hip. Clin. Rheumatol. 18: 4–9.PubMedCrossRefGoogle Scholar
  3. Bundesgesundheitsamt (1987): Monographie der Kommission E über Brennessel-krautextrakt. Bundesanzeiger Nr. 76 vom 23. April 1987.Google Scholar
  4. Burnham R., Gregg R., Healy P., Steadward R. (1998): The effectiveness of topical diclofenac for lateral epicondylitis. Clin. J. Sport Med. 8: 78–81.PubMedCrossRefGoogle Scholar
  5. Castell J.V., Friedrich G., Kuhn C.S., Poppe G.E. (1997): Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am. J. Physiol. 273: G139–G146.PubMedGoogle Scholar
  6. Cryer B., Feldman M. (1998): Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 104: 413–421.PubMedCrossRefGoogle Scholar
  7. Dequeker J., Hawkey C., Kahan A. et al. (1998): Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol. 37: 946–951.PubMedCrossRefGoogle Scholar
  8. Dickson DJ. (1991): A double-blind evaluation of topical piroxicam gel with oral ibuprofen in osteoarthritis of the knee. Curr. Ther. Res. 49: 199–207.Google Scholar
  9. Diebschlag W. (1986): Diclofenac bei stumpf-traumatischen Sprunggelenkschwellungen. Fortschr. Med. 104: 437–440.PubMedGoogle Scholar
  10. Drovanti A., Bignamini A.A., Rovati A.L. (1980): Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clin. Ther. 3: 260–272.PubMedGoogle Scholar
  11. Eccles M., Freemantle N., Mason J. (1998): North of England evidence based guideline development project: summary guideline for non steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. Brit. Med. J. 317: 526–530.PubMedCrossRefGoogle Scholar
  12. El Hadidi T., El Garf A. (1991): Double-blind study comparing the use of Voltaren Emulgel versus regular gel during ultrasonic sessions in the treatment of localized traumatic and rheumatic painful conditions. J. Int. Med. Res. 19: 219–227.PubMedGoogle Scholar
  13. Emery P., Zeidler H., Kvien T.K., Guslandi M., Naudin R., Stead H. et al. (1999): Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomized double blind comparison. Lancet 354: 2106–2111.PubMedCrossRefGoogle Scholar
  14. Evans J.M.M., MacDonald T.M. (1996): Tolerability of topical NSAIDs in the elderly. Drugs Aging 9: 101–108.PubMedCrossRefGoogle Scholar
  15. Gondolph-Zink B., Gronwald U. (1996): Wirkstoffkonzentrationen in artikulären und periartikulären Geweben des Kniegelenkes nach kutaner Anwendung von Diclofenac-Diethylammonium Emulgel. Akt. Rheumatol. 21: 298–304.CrossRefGoogle Scholar
  16. Grace D., Rogers J., Skeith K., Anderson K. (1999): Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee. J. Rheumatol. 26: 2659–2663.PubMedGoogle Scholar
  17. Gretzer B., Ehrlich K., Maricic N., Lambrecht N., Respondek M., Peskar B.M. (1998): Selective cyclo-oxygenase 2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Brit. J. Pharmacol. 123: 927–935.CrossRefGoogle Scholar
  18. Hawkey C.J. (1999): COX-2 inhibitors. Lancet 353: 307–314.PubMedCrossRefGoogle Scholar
  19. Hawkey C., Kahan A., Steinbrück K., Alegre C., Baumelou E. et al. (1998): Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br. J. Rheumatol. 37: 937–945.PubMedCrossRefGoogle Scholar
  20. Hosie G.A.C. (1993): The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. Br. J. Clin. Res. 4: 5–17.Google Scholar
  21. Hotz G., Frank T., Zoller J., Wiebelt H. (1989): Antiphlogistic effect of bromelaine following third molar removal. Dtsch. Zahnärztl. Z. 44: 830–832.PubMedGoogle Scholar
  22. Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H. et al. (1999): A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117: 776–783.PubMedCrossRefGoogle Scholar
  23. Langman M.J.S., Weil J., Wainwright P., Lawson D.H., Rawlins M.D. et al. (1994): Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 323: 1075-1052.Google Scholar
  24. Langman M.J., Jensen D.M., Watson DJ., Harper S.E., Zhao PL., Quan H. et al. (1999): Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDS. JAMA 282: 1929–1933.PubMedCrossRefGoogle Scholar
  25. Masson M. (1995): Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice. Fortschr. Med. 113: 303–306.Google Scholar
  26. McAlindon T.E., LaValley M.P., Gulin J.P., Felson D.T. (2000): Glucosamine and chondroitin for treatment of osteoarthritis. A systematic quality assessment and meta-analysis. JAMA 283: 1469–1475.Google Scholar
  27. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. (1993): Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90, 11693–11697.PubMedCrossRefGoogle Scholar
  28. Moore R.A., Tramèr M.R., Caroll D., Wiffen P.J., McQuay H.J. (1998): Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. Brit. Med. J. 316: 333–338.PubMedCrossRefGoogle Scholar
  29. Müller M., Mascher H., Kikuta C., Schäfer S., Brunner M. et al. (1997): Diclofenac concentrations in defined tissue layers after topical administration. Clin. Pharmacol. Ther. 62: 293–299.PubMedCrossRefGoogle Scholar
  30. Newberry R., Shuttleworth P., Rapier C. (1992): A multicentre postmarketing surveillance study to evaluate the safety and efficacy of felbinac 3 % gel in the treatment of musculoskeletal disorders in general practice. Eur. J. Clin. Res. 3: 139–150.Google Scholar
  31. Nocker W, Diebschlag W. (1991): Behandlung akuter Sprunggelenkdistorsionen. Z. All. Med. 67: 560–564.Google Scholar
  32. Obertreis B., Giller K., Teucher T., Behnke B., Schmitz H. (1996): Antiphlogistische Effekte von Extractum Urticae dioicae foliorum im Vergleich zu Kaffeoyläpfelsäure. Arzneim. Forsch. 46: 52–56.Google Scholar
  33. Pujalte J.M., Llavore E.P., Ylescupidez ER. (1980): Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr. Med. Res. Op. 7: 110–114.CrossRefGoogle Scholar
  34. Radermacher J., Jentsch D., Scholl M.A., Lustinetz T., Frölich J.C. (1991): Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br. J. Clin. Pharmac. 31: 537–541.CrossRefGoogle Scholar
  35. Reichelt A., Förster K.K., Fischer M., Rovati L.C., Setnikar I. (1994): Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. Arzneim. Forsch. 44: 75–80.Google Scholar
  36. Riess W., Schmid K., Botta L., Kobayashi K., Moppert J. et al. (1986): Die perkutane Resorption von Diclofenac. Arzneim. Forsch. 36: 1092–1096.Google Scholar
  37. Rindone J.P., Hiller D., Collacott E., Nordhaugen N., Arriola G. (2000): Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West. J. Med. 172: 91–94.PubMedCrossRefGoogle Scholar
  38. Roth S.H. (1995): A controlled clinical investigation of 3% diclofenac/2.5 % sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with osteoarthritis. Int. J. Tissue React. 17: 129–132.Google Scholar
  39. Rovati L.C. (1992): Clinical research in osteoarthritis: design and results of shortterm and long-term trials with disease-modifying drugs. Int. J. Tiss. Reac. 14: 243–251.Google Scholar
  40. Sandholzer H., Kochen M.M. (1991): Perkutane Rheumatherapie. Pharma-Kritik 13: 13–16.Google Scholar
  41. Schapira D., Linn S., Scharf Y. (1991): A placebo-controlled evaluation of diclofenac diethylamine salt in the treatment of lateral epicondylitis of the elbow. Curr. Ther. Res. 49: 162–168.Google Scholar
  42. Schubotz R., Hausmann L. (1977): Behandlung degenerativer Gelenkerkrankungen mit N-Azetyl-hydroxyprolin. Therapiewoche 27: 4248–4252.Google Scholar
  43. Setnikar I., Palumbo R., Canali S., Zanolo G. (1993): Pharmacokinetics of glucosamine in man. Arzneim. Forsch. 43: 1109–1113.Google Scholar
  44. Towheed T.E., Anastassiades T.P. (2000): Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete. JAMA 283: 1483–1484.PubMedCrossRefGoogle Scholar
  45. Vagt C.W., Kaiser T., Leineweber G. (1990): Wirksamkeitsvergleich der oralen Therapie mit Oxazeprol versus Ibuprofen bei Gonarthrose und Coxarthrose. Rheuma 10: 263–267.Google Scholar
  46. Wallace J.L., Bak A., McKnight W, Asfaha S., Sharkey K.A., Mac Naughton W.K. (1998): Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implilcations for gastrointestinal toxicity. Gastroenterology 115: 101–109.PubMedCrossRefGoogle Scholar
  47. Weiss R.F., Fintelmann V. (1997): Lehrbuch der Phytotherapie. 8. Aufl., Hippokrates Verlag Stuttgart, S. 271–281.Google Scholar
  48. Zeidler H. (1996): Nichtsteroidale Antiphlogistika. Neue Wege zu einer rationalen, sparsamen und risikoärmeren Verordnung. Akt. Rheumatol. 21: 269–271.CrossRefGoogle Scholar
  49. Zimmermann J., Siguencia J., Tsvang E. (1995): Upper gastrointestinal hemorrhage associated with cutaneous application of diclofenac gel. Am. J. Gastroenterol. 90: 2032–2034.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Gerhard Schmidt
    • 1
  1. 1.Institut für Pharmakologie und Toxikologie der UniversitätGöttingenDeutschland

Personalised recommendations